28 studies found for:    anti-GD2 monoclonal antibody
Show Display Options
Rank Status Study
1 Completed Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma
Interventions: Biological: monoclonal antibody Ch14.18;   Drug: isotretinoin;   Biological: aldesleukin;   Biological: sargramostim
2 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
3 Active, not recruiting Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: beta-glucan;   Biological: monoclonal antibody 3F8;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
4 Completed Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: beta-glucan;   Biological: monoclonal antibody 3F8
5 Completed ch14.18/CHO Bridging Study
Condition: Neuroblastoma
Intervention: Drug: ch14.18/CHO
6 Unknown  Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Condition: Neuroblastoma
Interventions: Drug: ch14.18/CHO;   Drug: Aldesleukin;   Drug: Isotretinoin
7 Recruiting Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Anti-GD2 3F8 Monoclonal Antibody;   Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor);   Drug: oral isotretinoin
8 Active, not recruiting Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: anti-GD2 murine IgG3 monoclonal antibody 3F8
9 Recruiting A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Humanized anti-GD2 antibody;   Drug: Chemotherapy;   Other: Cytokines;   Biological: Natural killer cells
10 Recruiting Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: lenalidomide;   Biological: dinutuximab;   Drug: isotretinoin;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Completed Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Condition: Neuroblastoma
Interventions: Biological: beta-glucan;   Biological: monoclonal antibody 3F8;   Biological: sargramostim;   Drug: isotretinoin
12 Completed Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neurotoxicity;   Pain;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: cytology specimen collection procedure;   Other: pharmacological study
13 Completed Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: monoclonal antibody 4B5 anti-idiotype vaccine;   Biological: sargramostim;   Drug: alum adjuvant
14 Recruiting A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
Conditions: Neuroblastoma;   Melanoma;   Osteosarcoma;   Ewing Sarcoma
Intervention: Biological: Anti-G2 antibody
15 Recruiting Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
Conditions: Ewings Family of Tumors;   Melanoma;   Neuroblastoma;   Osteosarcoma
Intervention:
16 Terminated S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: monoclonal antibody 11D10 anti-idiotype vaccine;   Biological: monoclonal antibody GD2 anti-idiotype vaccine;   Drug: cisplatin;   Drug: etoposide;   Radiation: radiation therapy
17 Completed Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
Conditions: Neuroblastoma;   Sarcoma
Interventions: Biological: BCG vaccine;   Biological: monoclonal antibody A1G4 anti-idiotype vaccine
18 Recruiting Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Condition: Neuroblastoma
Intervention: Drug: 3F8 Monoclonal Antibody Combined with Interleukin-2
19 Active, not recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
20 Active, not recruiting Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
Condition: Neuroblastoma
Intervention: Biological: 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) w/o lymphodepletion

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Indicates status has not been verified in more than two years